• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name:  (1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)
Date Designated:  10/25/2018
Orphan Designation:  Treatment of thymoma and thymic carcinoma
Orphan Designation Status:  Designated
FDA Orphan Approval Status:  Not FDA Approved for Orphan Indication
Phosplatin Therapeutics LLC
1350 6th Avenue
3rd Floor
New York, New York 10019
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.